BMGL
Basel Medical Group Ltd Ordinary SharesBMGL
BMGL
About: Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.
–
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for BMGL.
Financial journalist opinion
Based on 3 articles about BMGL published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Basel Medical Group Ltd Announces Closing of US$8,820,000 Initial Public Offering
Singapore, March 03, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (the “Company”) (Nasdaq: BMGL), a Singapore-based clinical provider of general and subspecialized orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments, today announced the closing of its initial public offering of 2,205,000 ordinary shares at a public offering price of US$4.00 per share. The shares commenced trading on the Nasdaq Capital Market on February 25, 2025, under the ticker symbol “BMGL”. The Company has registered for resale up to 2,000,000 existing ordinary shares by certain selling shareholders. The Company will not receive any proceeds from the sale of those shares by the selling shareholders.
Neutral
Seeking Alpha
2 weeks ago
U.S. IPO Weekly Recap: Small Asia-Based Names List, As TV Adtech MNTN And Others Join The Pipeline
Four IPOs and four SPACs listed this week. Four IPOs and two SPACs submitted initial filings. The March IPO market is set to start off with a quiet week.
Neutral
GlobeNewsWire
2 weeks ago
Basel Medical Group Ltd Prices US$8,820,000 Initial Public Offering
Singapore, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (the “Company”) (Nasdaq: BMGL), a Singapore-based clinical provider of general and subspecialized orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments, today announced the pricing of its initial public offering of 2,205,000 ordinary shares at a public offering price of US$4.00 per share. The shares are expected to commence trading on the Nasdaq Capital Market on February 25, 2025, under the ticker symbol “BMGL”. Concurrently, the Company has registered for resale up to 2,000,000 existing ordinary shares by certain selling shareholders. The Company will not receive any proceeds from the sale of those shares by the selling shareholders.
Charts implemented using Lightweight Charts™